This '90s shoe trend was all the rage at New York Fashion Week
It's New York Fashion Week, But the 'Ugly' Sandal Still Reigns – Footwear News
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Teva lied about opioid role, New York says
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis | News/Talk/Sports 94.9 WSJM
Teva reaches $523 million deal to settle opioid lawsuit with New York | CNN Business
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceuticals Takes Hit in New York Opioid Case
Teva to appeal New York jury ruling in opioids trial (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals found liable in New York opioid trial - BBC News
Teva Pharmaceuticals Found Liable in Landmark Opioid Trial - The New York Times
Teva Pharmaceuticals found liable in New York opioid trial - BBC News
New York Fashion Week Inspired Shoe Trends | Teva®
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
New York jury holds drug firm Teva liable in opioid crisis
Drugmaker Teva fueled opioid addiction in New York, jury finds | Reuters
Drugmaker Teva Misled Court to Dodge Opioid Trial, New York State Claims - Bloomberg
Teva to pay $523m. to New York as it looks to move past opioid lawsuits - The Jerusalem Post
La crisis de los opioides acaba con una multa millonaria a la farmacéutica Teva
Teva Pharmaceuticals May Have Lied in Opioid Case: NYAG
Teva lone New York defendant after Allergan opioid settlement - Globes
Wow, Tevas Got Cute - The New York Times
Teva Pharmaceuticals found liable for role in New York opioid epidemic - UPI.com
In opioid case, NY wants to probe Teva's control of Teva USA
New York to receive up to $524M from Teva in opioid settlement - syracuse.com
Teva shutters New York, D.C. offices and dismisses lobbyists as part of U.S. consolidation drive | Fierce Pharma
